FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Stem cell research & therapy2020; 11(1); 52; doi: 10.1186/s13287-020-1571-8

Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.

Abstract: Antibody production after allogeneic administration of mesenchymal stem cells (MSCs) could impact their clinical application. Proinflammatory priming of MSCs can potentiate their regulatory ability in vivo but increased expression of major histocompatibility complex (MHC) might augment their immunogenicity, potentially leading to immune memory thus limiting repeated allogeneic administration. This study aimed at evaluating the production of cytotoxic allo-antibodies directed against donor's ELA (equine leukocyte antigen) in mismatched and halfmatched horses receiving repeated intraarticular administration of stimulated MSCs (MSC-primed) and unstimulated MSCs (MSC-naïve) in pathologic joints. From available stored samples from a previous in vivo study, cells from one donor and serially collected sera (five time-points) from three groups of recipients were used based on their ELA haplotypes to perform microcytotoxicity assays: Group 1 recipients mismatched with the donor that received MSC-naïve (naïve-mismatched recipients); Group 2 recipients mismatched with the donor that received MSC-primed (primed-mismatched recipients); Group 3 recipients halfmatched with the donor (sharing 1/2 haplotypes) that received MSC-primed (primed-halfmatched recipients). Sera from recipients (neat, 1:2 and 1:16 dilution) were tested against target cells from the donor (cryopreserved and expanded MSC-naïve and MSC-primed) or from one animal presenting the same ELA haplotypes than the donor (fresh peripheral blood lymphocytes as control). One to three weeks after first MSC administration, all recipient groups produced allo-antibodies regardless of MSC received (naïve or primed) and matching degree with donor. However, secondary response after MSC re-exposure was less evident in halfmatched recipients (MSC-primed) than in mismatched ones (both MSC-naïve and MSC-primed). Recipients of MSC-primed (both mismatched and halfmatched) tended towards developing lower antibody response than MSC-naïve recipients in vivo, but MSC-primed were targeted to death in higher percentage in vitro in the microcytoxicity assay. After first intraarticular allogeneic administration, the immunomodulatory profile of MSC-primed would have led to lower antibody production, but these antibodies would target more easily MSC-primed after second injection (re-exposure), likely because of their higher MHC expression.
Get Full Text
Publication Date: 2020-02-07 PubMed ID: 32028995PubMed Central: PMC7006079DOI: 10.1186/s13287-020-1571-8Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper investigates the formation of harmful allo-antibodies after the allogenic administration of Mesenchymal Stem Cells (MSCs) in an equine model of osteoarthritis. Assessments are made of the antibody responses following repeated administrations and stimulation of the MSCs, with evaluations as to the importance of the recipient and donor’s compatibility with Equine Leukocyte Antigen (ELA).

Understanding the Study

  • The goal of the study was to determine the impact of allo-antibody production after allogeneic administration of MSCs, an important concern for their clinical application. Allo-antibodies are antibodies produced when an organism is exposed to cells or tissues from another member of the same species, which can potentially lead to adverse reactions.
  • Mesenchymal Stem Cells (MSCs) are multipotent stem cells can differentiate into various cell types. They have characteristics that may potentially be used in the treatment of diseases such as osteoarthritis.
  • Some factors, such as proinflammatory priming, can help improve MSC efficacy in vivo. However, they can also upregulate the expression of major histocompatibility complex (MHC), which might increase the production of allo-antibodies, leading to an immune response upon repeated administration.

Setting Up the Experiment

  • The experiment involved the administration of MSCs in equine models suffering from osteoarthritis, in mismatched and halfmatched horses. It aimed to examine if there was allo-antibody production against the Equine Leukocyte Antigen (ELA) present in donor cells.
  • Three different groups of recipient animals were created to examine the effects: mismatched recipients of MSC-naïve (new and unstressed MSCs); mismatched recipients of MSC-primed (proinflammatorily stimulated MSCs) and halfmatched recipients of MSC-primed.
  • The sera from the recipient animals were tested against target cells from the donor animals (both MSC-naïve and MSC-primed) to evaluate the production of antibodies, using a microcytotoxicity assay which measures the percentage of dead cells from exposure to the serum.

Results of the Experiment

  • The experiment found that allo-antibodies were developed by all recipient groups after the first administration of MSCs, irrespective of the form of MSCs and matching degree.
  • The halfmatched recipients who received MSC-primed showed less secondary reaction, or antibody response, upon re-exposure to MSCs. This indicates that the ELA compatibility between the donor and recipient influences the immune response.
  • The study also found evidence suggesting in initial MSC-primed administrations, there might be a lesser antibody response than to MSC-naïve. However, upon subsequent exposure, the MSC-primed might be more easily targeted for destruction by the immune system because of their higher MHC expression level.

Implications and Conclusions

  • Overall, this research shows that allo-antibodies produced in response to allogeneic MSC injections can potentially limit the effectiveness of repeated MSC injections due to the body mounting an immune response.
  • This shows that using MSCs in number of medical treatments might be problematic due to the allo-antibody generation, especially for repeated administration or mismatched donors.
  • This research brings up questions about the most effective use of MSCs in treatment procedures, particularly around issues of compatibility, pre-treatment of MSCs (priming), and the schedule of administration.

Cite This Article

APA
Barrachina L, Cequier A, Romero A, Vitoria A, Zaragoza P, Vázquez FJ, Rodellar C. (2020). Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility. Stem Cell Res Ther, 11(1), 52. https://doi.org/10.1186/s13287-020-1571-8

Publication

Stem cell research & therapy
ISSN: 1757-6512
NlmUniqueID: 101527581
Country: England
Language: English
Volume: 11
Issue: 1
Pages: 52
PII: 52

Researcher Affiliations

Barrachina, Laura
  • Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
  • Instituto Agroalimentario de Aragón (IA2), Universidad de Zaragoza - CITA, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
Cequier, Alina
  • Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
  • Instituto Agroalimentario de Aragón (IA2), Universidad de Zaragoza - CITA, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
Romero, Antonio
  • Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
Vitoria, Arantza
  • Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
Zaragoza, Pilar
  • Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
  • Instituto Agroalimentario de Aragón (IA2), Universidad de Zaragoza - CITA, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
Vázquez, Francisco José
  • Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
  • Servicio de Cirugía y Medicina Equina, Hospital Veterinario, Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain.
Rodellar, Clementina
  • Laboratorio de Genética Bioquímica LAGENBIO - Instituto de Investigación Sanitaria de Aragón (IIS), Universidad de Zaragoza, C/Miguel Servet, 177, 50013, Zaragoza, Spain. rodellar@unizar.es.
  • Instituto Agroalimentario de Aragón (IA2), Universidad de Zaragoza - CITA, C/Miguel Servet, 177, 50013, Zaragoza, Spain. rodellar@unizar.es.

MeSH Terms

  • Animals
  • Disease Models, Animal
  • Female
  • Horses
  • Immunomodulation / immunology
  • Leukocytes / immunology
  • Male
  • Mesenchymal Stem Cell Transplantation / methods
  • Mesenchymal Stem Cells / metabolism
  • Osteoarthritis

Grant Funding

  • AGL2017-84411-P / Ministerio de Economu00eda, Industria y Competitividad, Gobierno de Espau00f1a
  • A19_17R / Gobierno de Aragu00f3n
  • Pre-doctoral scholarship / Gobierno de Aragu00f3n

Conflict of Interest Statement

The authors declare that they have no competing interests.

References

This article includes 29 references
  1. Halper J, Kim B, Khan A, Yoon JH, Mueller PO. Degenerative suspensory ligament desmitis as a systemic disorder characterized by proteoglycan accumulation.. BMC Vet Res 2006 Apr 12;2:12.
    doi: 10.1186/1746-6148-2-12pmc: PMC1459153pubmed: 16611357google scholar: lookup
  2. Colbath AC, Frisbie DD, Dow SW, Kisiday JD, McIlwraith CW, Goodrich LR. Equine models for the investigation of mesenchymal stem cell therapies in orthopedic disease.. Oper Tech Sport Med 2017;25(1):41–49.
    doi: 10.1053/j.otsm.2016.12.007google scholar: lookup
  3. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair.. Nat Rev Rheumatol 2013 Oct;9(10):584-94.
    doi: 10.1038/nrrheum.2013.109pubmed: 23881068google scholar: lookup
  4. Cuerquis J, Romieu-Mourez R, François M, Routy JP, Young YK, Zhao J, Eliopoulos N. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation.. Cytotherapy 2014 Feb;16(2):191-202.
    doi: 10.1016/j.jcyt.2013.11.008pubmed: 24438900google scholar: lookup
  5. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged.. Nat Biotechnol 2014 Mar;32(3):252-60.
    doi: 10.1038/nbt.2816pmc: PMC4320647pubmed: 24561556google scholar: lookup
  6. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response.. Biol Blood Marrow Transplant 2007 Apr;13(4):412-22.
    doi: 10.1016/j.bbmt.2006.12.447pmc: PMC1892590pubmed: 17382248google scholar: lookup
  7. Ryan AE, Lohan P, O'Flynn L, Treacy O, Chen X, Coleman C, Shaw G, Murphy M, Barry F, Griffin MD, Ritter T. Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation.. Mol Ther 2014 Mar;22(3):655-667.
    doi: 10.1038/mt.2013.261pmc: PMC3944342pubmed: 24184966google scholar: lookup
  8. Isakova IA, Lanclos C, Bruhn J, Kuroda MJ, Baker KC, Krishnappa V, Phinney DG. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo.. PLoS One 2014;9(1):e87238.
    doi: 10.1371/journal.pone.0087238pmc: PMC3906169pubmed: 24489878google scholar: lookup
  9. Beggs KJ, Lyubimov A, Borneman JN, Bartholomew A, Moseley A, Dodds R, Archambault MP, Smith AK, McIntosh KR. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons.. Cell Transplant 2006;15(8-9):711-21.
    doi: 10.3727/000000006783981503pubmed: 17269442google scholar: lookup
  10. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, Murphy M, O'Brien T, Ritter T. Immunogenicity of allogeneic mesenchymal stem cells.. J Cell Mol Med 2012 Sep;16(9):2094-103.
    doi: 10.1111/j.1582-4934.2011.01509.xpmc: PMC3822979pubmed: 22151542google scholar: lookup
  11. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo.. Transplantation 2007 Mar 27;83(6):783-90.
    doi: 10.1097/01.tp.0000258649.23081.a3pubmed: 17414713google scholar: lookup
  12. Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP, Harris IR, Popma SH, Sachs DH, Huang CA. Immunogenicity of umbilical cord tissue derived cells.. Blood 2008 Jan 1;111(1):430-8.
    doi: 10.1182/blood-2007-03-078774pubmed: 17909081google scholar: lookup
  13. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  14. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  15. Owens SD, Kol A, Walker NJ, Borjesson DL. Allogeneic Mesenchymal Stem Cell Treatment Induces Specific Alloantibodies in Horses.. Stem Cells Int 2016;2016:5830103.
    doi: 10.1155/2016/5830103pmc: PMC5018342pubmed: 27648075google scholar: lookup
  16. Barrachina L, Remacha AR, Romero A, Vitoria A, Albareda J, Prades M, Roca M, Zaragoza P, Vázquez FJ, Rodellar C. Assessment of effectiveness and safety of repeat administration of proinflammatory primed allogeneic mesenchymal stem cells in an equine model of chemically induced osteoarthritis.. BMC Vet Res 2018 Aug 17;14(1):241.
    doi: 10.1186/s12917-018-1556-3pmc: PMC6098603pubmed: 30119668google scholar: lookup
  17. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Gosálvez J, Roy R, Zaragoza P, Martín-Burriel I, Rodellar C. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.. Stem Cells Dev 2017 Jan 1;26(1):15-24.
    doi: 10.1089/scd.2016.0209pubmed: 27712399google scholar: lookup
  18. Sadeghi R, Moradi-Shahrbabak M, Miraei Ashtiani SR, Miller DC, Antczak DF. MHC haplotype diversity in Persian Arabian horses determined using polymorphic microsatellites.. Immunogenetics 2018 May;70(5):305-315.
    doi: 10.1007/s00251-017-1039-xpubmed: 29170799google scholar: lookup
  19. Tseng CT, Miller D, Cassano J, Bailey E, Antczak DF. Identification of equine major histocompatibility complex haplotypes using polymorphic microsatellites.. Anim Genet 2010 Dec;41 Suppl 2(Suppl 2):150-3.
    doi: 10.1111/j.1365-2052.2010.02125.xpmc: PMC3289534pubmed: 21070289google scholar: lookup
  20. Brinkmeyer-Langford CL, Cai JJ, Gill CA, Skow LC. Microsatellite variation in the equine MHC.. Anim Genet 2013 Jun;44(3):267-75.
    doi: 10.1111/age.12003pubmed: 23051181google scholar: lookup
  21. Siqueira RF, Fernandes LR. Cryopreservation of lymphocytes for immunological studies in horses.. Pesqui Vet Brasil 2018;38:2019–2022.
    doi: 10.1590/1678-5150-pvb-5419google scholar: lookup
  22. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  23. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Ranera B, Zaragoza P, Martín-Burriel I, Rodellar C. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.. Vet Immunol Immunopathol 2016 Mar;171:57-65.
    doi: 10.1016/j.vetimm.2016.02.007pubmed: 26964718google scholar: lookup
  24. Holmes CM, Violette N, Miller D, Wagner B, Svansson V, Antczak DF. MHC haplotype diversity in Icelandic horses determined by polymorphic microsatellites.. Genes Immun 2019 Nov;20(8):660-670.
    doi: 10.1038/s41435-019-0075-ypubmed: 31068686google scholar: lookup
  25. Ademokun AA, Dunn-Walters D. Immune responses: primary and secondary. eLS Chichester: Wiley; 2010; p. eLS2010.
  26. García-Sancho J, Sánchez A, Vega A, Noriega DC, Nocito M. Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease.. Transplant Direct 2017 Sep;3(9):e205.
    doi: 10.1097/TXD.0000000000000724pmc: PMC5585421pubmed: 28894792google scholar: lookup
  27. Wang Y, Shimmin A, Ghosh P, Marks P, Linklater J, Connell D, Hall S, Skerrett D, Itescu S, Cicuttini FM. Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial.. Arthritis Res Ther 2017 Aug 2;19(1):180.
    doi: 10.1186/s13075-017-1391-0pmc: PMC5541727pubmed: 28768528google scholar: lookup
  28. Avivar-Valderas A, Martín-Martín C, Ramírez C, Del Río B, Menta R, Mancheño-Corvo P, Ortiz-Virumbrales M, Herrero-Méndez Á, Panés J, García-Olmo D, Castañer JL, Palacios I, Lombardo E, Dalemans W, DelaRosa O. Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn's Disease Patients.. Front Immunol 2019;10:1244.
    doi: 10.3389/fimmu.2019.01244pmc: PMC6587893pubmed: 31258526google scholar: lookup
  29. Salmon JK, Armstrong CA, Ansel JC. The skin as an immune organ.. West J Med 1994 Feb;160(2):146-52.
    pmc: PMC1022320pubmed: 8160465

Citations

This article has been cited 25 times.
  1. Dai P, Wu Y, Du Q, Du J, Wang K, Chen R, Feng X, Chen C, Zhang X. Knockout of B2M in combination with PD-L1 overexpression protects MSC-derived new islet β cells from graft rejection in the treatment of canine diabetes mellitus. Stem Cell Res Ther 2024 Dec 2;15(1):458.
    doi: 10.1186/s13287-024-04067-7pubmed: 39623490google scholar: lookup
  2. Yaneselli K, Ávila G, Rossi A, Rial A, Castro S, Estradé MJ, Suárez G, Algorta A. Impact of different formulations of platelet lysate on proliferative and immune profile of equine mesenchymal stromal cells. Front Vet Sci 2024;11:1410855.
    doi: 10.3389/fvets.2024.1410855pubmed: 39161460google scholar: lookup
  3. Cequier A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Serrano MB, Zaragoza MP, Romero A, Rodellar C, Barrachina L. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse. Front Vet Sci 2024;11:1391872.
    doi: 10.3389/fvets.2024.1391872pubmed: 38957800google scholar: lookup
  4. Reis IL, Lopes B, Sousa P, Sousa AC, Rêma A, Caseiro AR, Briote I, Rocha AM, Pereira JP, Mendonça CM, Santos JM, Lamas L, Atayde LM, Alvites RD, Maurício AC. Case report: Equine metacarpophalangeal joint partial and full thickness defects treated with allogenic equine synovial membrane mesenchymal stem/stromal cell combined with umbilical cord mesenchymal stem/stromal cell conditioned medium. Front Vet Sci 2024;11:1403174.
    doi: 10.3389/fvets.2024.1403174pubmed: 38840629google scholar: lookup
  5. Burk J, Wittenberg-Voges L, Schubert S, Horstmeier C, Brehm W, Geburek F. Treatment of Naturally Occurring Tendon Disease with Allogeneic Multipotent Mesenchymal Stromal Cells: A Randomized, Controlled, Triple-Blinded Pilot Study in Horses. Cells 2023 Oct 24;12(21).
    doi: 10.3390/cells12212513pubmed: 37947591google scholar: lookup
  6. Vasoya D, Tzelos T, Benedictus L, Karagianni AE, Pirie S, Marr C, Oddsdóttir C, Fintl C, Connelley T. High-Resolution Genotyping of Expressed Equine MHC Reveals a Highly Complex MHC Structure. Genes (Basel) 2023 Jul 10;14(7).
    doi: 10.3390/genes14071422pubmed: 37510326google scholar: lookup
  7. Copp G, Robb KP, Viswanathan S. Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol 2023 Jun;20(6):626-650.
    doi: 10.1038/s41423-023-01020-1pubmed: 37095295google scholar: lookup
  8. Xu Y, Fan P, Liu L, Xuanfei XU, Zhang L, Wang J, Tao Y, Li X, Li X, Wang Y. Novel perspective in transplantation therapy of mesenchymal stem cells: targeting the ferroptosis pathway. J Zhejiang Univ Sci B 2023 Feb 15;24(2):115-129.
    doi: 10.1631/jzus.B2200410pubmed: 36751698google scholar: lookup
  9. Cequier A, Vázquez FJ, Romero A, Vitoria A, Bernad E, García-Martínez M, Gascón I, Barrachina L, Rodellar C. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility. Front Vet Sci 2022;9:957153.
    doi: 10.3389/fvets.2022.957153pubmed: 36337202google scholar: lookup
  10. Even KM, Gaesser AM, Ciamillo SA, Linardi RL, Ortved KF. Comparing the immunomodulatory properties of equine BM-MSCs culture expanded in autologous platelet lysate, pooled platelet lysate, equine serum and fetal bovine serum supplemented culture media. Front Vet Sci 2022;9:958724.
    doi: 10.3389/fvets.2022.958724pubmed: 36090170google scholar: lookup
  11. Andersen C, Uvebrant K, Mori Y, Aarsvold S, Jacobsen S, Berg LC, Lundgren-Åkerlund E, Lindegaard C. Human integrin α10β1-selected mesenchymal stem cells home to cartilage defects in the rabbit knee and assume a chondrocyte-like phenotype. Stem Cell Res Ther 2022 May 16;13(1):206.
    doi: 10.1186/s13287-022-02884-2pubmed: 35578319google scholar: lookup
  12. Rosa GDS, Krieck AMT, Padula ET, Stievani FC, Rossi MC, Pfeifer JPH, Basso RM, Braz AMM, Golim MA, Alves ALG. Production of Cytotoxic Antibodies After Intra-Articular Injection of Allogeneic Synovial Membrane Mesenchymal Stem Cells With and Without LPS Administration. Front Immunol 2022;13:871216.
    doi: 10.3389/fimmu.2022.871216pubmed: 35572507google scholar: lookup
  13. Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Zaragoza P, Rodellar C, Barrachina L. Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility. Animals (Basel) 2022 Apr 11;12(8).
    doi: 10.3390/ani12080984pubmed: 35454231google scholar: lookup
  14. Depuydt E, Broeckx SY, Chiers K, Patruno M, Da Dalt L, Duchateau L, Saunders J, Pille F, Martens A, Van Hecke L, Spaas JH. Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries. Front Vet Sci 2021;8:789293.
    doi: 10.3389/fvets.2021.789293pubmed: 35281431google scholar: lookup
  15. Estrada McDermott J, Pezzanite L, Goodrich L, Santangelo K, Chow L, Dow S, Wheat W. Role of Innate Immunity in Initiation and Progression of Osteoarthritis, with Emphasis on Horses. Animals (Basel) 2021 Nov 13;11(11).
    doi: 10.3390/ani11113247pubmed: 34827979google scholar: lookup
  16. Yue D, Du L, Zhang B, Wu H, Yang Q, Wang M, Pan J. Time-dependently Appeared Microenvironmental Changes and Mechanism after Cartilage or Joint Damage and the Influences on Cartilage Regeneration. Organogenesis 2021 Oct 2;17(3-4):85-99.
    doi: 10.1080/15476278.2021.1991199pubmed: 34806543google scholar: lookup
  17. Kamm JL, Riley CB, Parlane NA, Gee EK, McIlwraith CW. Immune response to allogeneic equine mesenchymal stromal cells. Stem Cell Res Ther 2021 Nov 12;12(1):570.
    doi: 10.1186/s13287-021-02624-ypubmed: 34772445google scholar: lookup
  18. Rowland AL, Burns ME, Levine GJ, Watts AE. Preparation Technique Affects Recipient Immune Targeting of Autologous Mesenchymal Stem Cells. Front Vet Sci 2021;8:724041.
    doi: 10.3389/fvets.2021.724041pubmed: 34595230google scholar: lookup
  19. Sanabria-de la Torre R, Quiñones-Vico MI, Fernández-González A, Sánchez-Díaz M, Montero-Vílchez T, Sierra-Sánchez Á, Arias-Santiago S. Alloreactive Immune Response Associated to Human Mesenchymal Stromal Cells Treatment: A Systematic Review. J Clin Med 2021 Jul 5;10(13).
    doi: 10.3390/jcm10132991pubmed: 34279481google scholar: lookup
  20. Rady D, Abbass MMS, El-Rashidy AA, El Moshy S, Radwan IA, Dörfer CE, Fawzy El-Sayed KM. Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation. Stem Cells Int 2020;2020:8837654.
    doi: 10.1155/2020/8837654pubmed: 33953753google scholar: lookup
  21. Harman RM, Marx C, Van de Walle GR. Translational Animal Models Provide Insight Into Mesenchymal Stromal Cell (MSC) Secretome Therapy. Front Cell Dev Biol 2021;9:654885.
    doi: 10.3389/fcell.2021.654885pubmed: 33869217google scholar: lookup
  22. Kamm JL, Riley CB, Parlane N, Gee EK, McIlwraith CW. Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes. Front Vet Sci 2020;7:617647.
    doi: 10.3389/fvets.2020.617647pubmed: 33521090google scholar: lookup
  23. Ribitsch I, Oreff GL, Jenner F. Regenerative Medicine for Equine Musculoskeletal Diseases. Animals (Basel) 2021 Jan 19;11(1).
    doi: 10.3390/ani11010234pubmed: 33477808google scholar: lookup
  24. Rowland AL, Miller D, Berglund A, Schnabel LV, Levine GJ, Antczak DF, Watts AE. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting. Stem Cells Transl Med 2021 May;10(5):694-710.
    doi: 10.1002/sctm.20-0435pubmed: 33369287google scholar: lookup
  25. Zhou H, Li X, Yin Y, He XT, An Y, Tian BM, Hong YL, Wu LA, Chen FM. The proangiogenic effects of extracellular vesicles secreted by dental pulp stem cells derived from periodontally compromised teeth. Stem Cell Res Ther 2020 Mar 6;11(1):110.
    doi: 10.1186/s13287-020-01614-wpubmed: 32143712google scholar: lookup
Subscribe to our newsletter
Join 99,780 horse owners like you who receive our email updates on horse health and nutrition.